Immunomodulation by Imiquimod in Patients with High-Risk Primary Melanoma
- 1 January 2012
- journal article
- research article
- Published by Elsevier BV in Journal of Investigative Dermatology
- Vol. 132 (1), 163-169
- https://doi.org/10.1038/jid.2011.247
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- A Functional Toll‐Like Receptor 8 Variant Is Associated with HIV Disease RestrictionThe Journal of Infectious Diseases, 2008
- Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanomaBritish Journal of Dermatology, 2008
- Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanomaJournal of Translational Medicine, 2008
- Treatment of Lentigo Maligna with Imiquimod before Staged ExcisionDermatologic Surgery, 2007
- Association of TLR7 single nucleotide polymorphisms with chronic HCV‐infection and response to interferon‐a‐based therapyJournal of Viral Hepatitis, 2007
- Immune responses in the draining lymph nodes against cancer: Implications for immunotherapyCancer and Metastasis Reviews, 2006
- Dendritic cell dysfunction in cancer: A mechanism for immunosuppressionImmunology & Cell Biology, 2005
- TLR signaling pathwaysSeminars in Immunology, 2004
- Interferon-α and Interleukin-12 Are Induced Differentially by Toll-like Receptor 7 Ligands in Human Blood Dendritic Cell SubsetsThe Journal of Experimental Medicine, 2002
- Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathwayNature Immunology, 2002